“…p16 plays a pivotal role in various tumor types including cancers of colon, skin, and gallbladder (reviewed in [6]). In breast cancer, studies on 10–314 patients suggested a role of p16 overexpression in tumor progression [7–10], metastasis [10], and clinical outcome [9, 10]. It is, thus, remarkable that deletion of the chromosomal region 9p21, potentially leading to reduced p16 expression, belongs to the most frequent deletions in breast cancers occurring in 11% to 65% [11–17].…”